Lexicon Pharmaceuticals LXRX
NASDAQ LXRX
$1.87 +0.01 (+0.54%)
At close: Nov 11, 2026 · 4:00 PM EST

Lexicon Pharmaceuticals (LXRX) Return on Sales [ROS] (2009 - 2026)

Updated

Lexicon Pharmaceuticals' Return on Sales [ROS] was -3835.26% in Q2 2026, down 3848.20 percentage points from 12.94% a year earlier and down 3830.54 percentage points from the prior quarter.

Analysis

Lexicon Pharmaceuticals (LXRX) Return on Sales [ROS] (2009 - 2026) Analysis & Trends

On a trailing twelve-month basis, Lexicon Pharmaceuticals' Return on Sales [ROS] was -131.43% through Jun 30, 2026, up 71.15 percentage points year-over-year; for FY2025, it came in at -98.21%, up 536.00 percentage points from FY2024.

  • Return on Sales [ROS] has now increased for three consecutive years, with a five-year change of +101.00 percentage points (FY2020 to FY2025).
  • In earlier years, Return on Sales [ROS] was -634.20% in FY2024 (+13630.75 pp), -14264.95% in FY2023 (+58224.26 pp), -72489.21% in FY2022 (-43264.38 pp) and -29224.83% in FY2021 (-29025.62 pp).
  • The Q2 2026 figure marks the lowest quarterly Return on Sales [ROS] since Q1 2024.
  • Compared with a year earlier, Return on Sales [ROS] was higher in six of the last eight quarters, with an average year-over-year change of +5058.97 percentage points.
  • The best year-over-year quarter for Return on Sales [ROS] over five years was Q1 2024 (a gain of 125746.56 percentage points); the worst was Q4 2021 (a drop of 177180.83 percentage points).
  • Per Business Quant data, LXRX's Return on Sales [ROS] in the three quarters before Q2 2026 was -4.72% (Q1 2026), -269.07% (Q4 2025) and -85.93% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 24.35%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 36.01%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 30.74%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 29.12%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 35.79%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 41.71%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 32.98%
10 Lexicon Pharmaceuticals 831.26 Mn 190.55 Mn 11.17 Mn -128.84%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -128.84%
Jun 30, 2026 -3,835.26%
Mar 31, 2026 -4.72%
Dec 31, 2025 -269.07%
Sep 30, 2025 -85.93%
Jun 30, 2025 12.94%
Mar 31, 2025 -2,034.79%
Dec 31, 2024 -123.28%
Sep 30, 2024 -3,639.60%
Jun 30, 2024 -3,360.90%
Mar 31, 2024 -4,011.77%
Dec 31, 2023 -6,657.69%
Sep 30, 2023 -30,636.42%
Jun 30, 2023 -13,955.84%
Mar 31, 2023 -129,758.33%
Dec 31, 2022 -108,135.71%
Sep 30, 2022 -59,217.95%
Jun 30, 2022 -68,591.43%
Dec 31, 2021 -180,928.57%
Sep 30, 2021 -99,834.78%
API Access

Lexicon Pharmaceuticals Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=LXRX&period=max&api_key=YOUR_API_KEY